- Additional research centers now enrolling patients in Australia and New 
  Zealand


- Company has achieved 50 percent of target enrollment in global Phase 3 trial


AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company 
focusing on rare childhood-onset neurogenetic disorders with limited or no 
treatment options, today announced the completion of activation of two 
additional clinical trial sites in Australia and New Zealand for its pivotal 
REACH-CDM study evaluating the efficacy and safety of the investigational 
therapy AMO-02 (tideglusib) in the treatment of congenital myotonic dystrophy 
(CDM1). The company also announced that the trial has recently passed 50 
percent enrollment.


"CDM1 is the most severe and earliest occurring form of myotonic dystrophy, 
with patients often experiencing cognitive and critical thinking challenges, 
speech impairment, muscle weakness and autism-like symptoms beginning shortly 
after birth," said Dr. Joseph Horrigan, Chief Medical Officer at AMO Pharma. 
"As a physician focused on studying pediatric neurogenetic diseases, it is 
especially exciting to initiate this landmark clinical trial for CDM1 in 
patients who reside in Australia and New Zealand, which represents a 
significant advance in research to develop an effective treatment for this 
underserved community."


The REACH-CDM trial now has multiple sites enrolling patients in the U.S., 
Canada, New Zealand and Australia, with additional sites planned. The recently 
activated participating centers are:


   -  New Zealand Clinical Research (NZCR), Auckland, New Zealand
      Principal investigator: Dr. Gina O'Grady
   -  Sydney Children's Hospital Network, Randwick, New South Wales, Australia
      Principal investigator: Dr. Michelle Farrar


The REACH-CDM trial will enroll a total of 56 patients. Upon completion of the 
trial, patients will have the opportunity to transition to the REACH-CDM X 
study, a 52-week open-label study designed to evaluate the long-term safety and 
efficacy of AMO-02.


"Achievement of 50% enrollment is a key milestone towards completion of the 
REACH-CDM trial and our efforts to advance the development of AMO-02 as a 
treatment for congenital myotonic dystrophy," said Dr. Michael Snape, Chief 
Scientific Officer at AMO Pharma. "We are very proud of our progress to date. 
With 12 global research centers now actively recruiting, we also very much 
appreciate the support from our outstanding team of investigators as well as 
the patients and caregivers for their continued commitment to participating in 
this study despite the challenging circumstances caused by the COVID-19 
pandemic."


To learn more about the REACH-CDM trial including a list of treatment centers, 
visit www.reachcdm.com.


About AMO-02


AMO-02 (tideglusib) is in development for the treatment of congenital myotonic 
dystrophy and has potential for use in additional CNS, neuromuscular and other 
orphan indications. AM0-02 is a clinical stage investigational medicine for the 
treatment of the severe form of congenital myotonic dystrophy known as DM1 or 
Steinert disease. AMO-02 has a dual mechanism disrupting the pathogenic RNA 
repeat in CDM1 and inhibiting excess levels of the kinase GSK3β.


About AMO Pharma


AMO Pharma is a biopharmaceutical company working to identify and advance 
promising therapies for the treatment of serious and debilitating diseases in 
patient populations with significant areas of unmet need, including rare and 
severe childhood onset neurogenetic disorders with limited or no treatment 
options. In addition to developing AMO-02 for congenital myotonic dystrophy, 
the company is also progressing AMO-01 as a clinical stage treatment for 
Phelan-McDermid syndrome and AMO-04 as a clinic-ready potential medicine for 
Rett syndrome and related disorders. AMO-02, AMO-01 and AMO-04 are 
investigational medicines that have not yet been approved for the treatment of 
patients anywhere in the world. For more information, please visit the AMO 
Pharma website at http://www.amo-pharma.com/.


Contacts


Media:
Bill Berry
Berry & Company Public Relations
bberry@berrypr.com
+1 212 253 8881


SOURCE AMO Pharma Limited